Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Small subset of cells has big role in controlling immunity, study finds

18.08.2003


A small subset of cells that tells the immune system whether to attack may be a future target for therapies to help patients fight tumors and keep transplanted organs, a Medical College of Georgia researcher says.


Dr. Andrew L. Mellor, director of MCG’s Immunotherapy Center.



Dendritic cells roam the body, picking up invaders, such as a virus or cancer, then show their finds to the T-cells and tell them how to respond, says Dr. Andrew L. Mellor, molecular geneticist and immunologist and director of the MCG Immunotherapy Center.

Work published in the Aug. 15 issue of The Journal of Immunology by Dr. Mellor and his colleagues gives further clues over what direction dendritic cells will give.


They have shown that giving mice an experimental immunosuppressive agent causes a select number of these cells to express an enzyme, indoleamine 2,3 dioxygenase, or IDO, and that those cells tell T-cells not to respond.

"They are a very fascinating new subset of dendritic cells previously not recognized," says Dr. Mellor, Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics. "We do not think all dendritic cells have the capacity to express IDO. The magic of this subset is their ability to do that," he said of the enzyme first identified for its role in helping a fetus escape rejection by the mother’s immune system.

"One of the things we argue in this paper is that we can use IDO to help us find out if dendritic cells are going to stimulate the immune system or turn it off. If they express IDO, they will not stimulate T cells to respond. If they don’t express IDO, they are likely to stimulate immune responses once they mature," Dr. Mellor says.

Five years ago nearly to the day, Dr. Mellor and his colleagues, Drs. David Munn and Simon Conway, were reporting in the journal Science that the developing fetus uses IDO to locally disable the mother’s immune system. It works by degrading tryptophan, an amino acid critical to the survival of T-cells, which get their action cues from dendritic cells.

The MCG scientists have focused many of their efforts since on how to use the IDO mechanism to manipulate the immune system to the patient’s advantage. In the case of transplant patients, they want the immune system to ignore the new organ; in the case of autoimmune diseases such as type 1 diabetes, they want it to stop a self-destructive attack on pancreas cells that produce insulin. Conversely, they want to prompt the immune system to destroy persistent tumors. In fact, their subsequent studies have shown some tumors express IDO, apparently much as the fetus, which may help them escape the immune response. Persistent infections such as HIV, the virus that causes AIDS, may also rely on the IDO mechanism to avoid destruction by the patients’ immune system.

A second Science paper by Drs. Munn and Mellor in September 2002 reported that human dendritic cells could express IDO and showed how the expression suppressed the proliferation of T-cells. "The idea of it simply being expressed in the dendritic cells completely alters our understanding of how dendritic cells talk to T-cells," Dr. Mellor says. "What is it that makes a dendritic cell decide to express IDO or not, that is the key question."

Now in animal studies they have made a select number of dendritic cells do just that by giving the drug CTLA4-Ig, a reagent designed to block the action of T-cells. The reagent is still in clinical trials to evaluate its potential for patients with transplants and autoimmune diseases such as multiple sclerosis. In November, scientists from the University of Perugia in Italy were the first to report that treatment with CTLA4-Ig induced the IDO mechanism in dendritic cells, a move that ultimately keeps T-cells from responding.

Although dendritic cells were believed to be a fairly homogenous group, the MCG scientists have shown that only a small number of the cells respond to the reagent. They also used the IDO knockout mice developed at MCG to prove that IDO has to be present for the reagent to have maximal effect, Dr. Mellor says.

These findings take the researchers closer to their goal of targeted manipulation of the immune system. "In principal we can use the new immunosuppressive drug to do that. We can treat mice with the reagent, and introduce antigens that their immune systems would normally respond vigorously to. The prediction is that the mouse treated with this reagent will no longer respond vigorously to these antigens. Our preliminary data indicates that we are on the right track."

In fact, the Perugia scientists have shown that the mouse model for type 1 diabetes has a specific defect in the IDO mechanism. "That means that if you have a defect in that mechanism, those mice and, therefore by extrapolation, human beings too, are much more likely to get type 1 diabetes." That knowledge needs to be used to help eliminate or at least reduce the risk of children identified at risk, Dr. Mellor said, referencing a large newborn screening program for type 1 diabetes under way by Dr. Jin-Xiong She, director of the MCG Center for Biotechnology and Genomic Medicine and Georgia Research Alliance Scholar in Genomic Medicine. "We have to use our immunology knowledge to protect patients at risk from getting diabetes," Dr. Mellor said.

When the immune system is not responsive enough, such as in the case of a tumor, they can block the IDO mechanism in the cells so they would regain the ability to attack. His colleague, Dr. Munn, is moving toward clinical trials on blocking this mechanism pharmacologically, much as they did in the early days to show the role of IDO in helping a fetus avoid rejection.

"It comes back to the unifying theme of what it is at the molecular and cellular level that regulates whether the immune system is going to respond or not to any given circumstance," Dr. Mellor says. "That is what we are working on and the results reported in this paper represent a significant breakthrough in understanding how to control immune responses."


###
The MCG researchers have funding from the National Institutes of Health and Carlos and Marguerite Mason Trust.

Toni Baker | EurekAlert!
Further information:
http://www.mcg.edu/

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>